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INTRODUCTION
Globally significant progress has been made in re-
ducing malaria morbidity and mortality. Between 2000
and 2010, malaria mortality rate fell by 26% around the
world, with 33% reduction in the African Region. Dur-
ing this period, an estimated 1.1 million malaria deaths
were averted globally, primarily as a result of a scaling-
up of interventions1. In spite of the progress, malaria re-
mains a major public health problem of concern globally.
The disease is endemic in 104 countries and transmission
is ongoing in 99 countries in 20122. Based on the latest
estimates by WHO, there were an estimated 219 million
cases of malaria (range 154–289 million) and 660,000
deaths (range 610,000–971,000) in 20102. It is respon-
sible for over 7% of deaths in children under five years in
developing countries3; therefore, it is one of the leading
causes of deaths among children. At global level malaria
is considered as a problem mainly in the African conti-
nent as the same contributes around 88% of the total re-
ported cases (microscopically confirmed + rapid diagnos-
tic test—RDT confirmed) and 97% the reported deaths.
The malaria problem is always associated with Africa due
to very high burden of the disease in that continent. How-
ever, malaria inflicts the heaviest toll in several countries
in Asia where it still remains at significant level and af-
fects socioeconomic development. As Asian countries are
undergoing rapid economic growth, these are also work-
ing together in addressing common challenges such as
malaria. During the 7th East Asia Summit in November
2012, the leaders adopted a joint declaration for regional
responses to control malaria and address the resistance to
antimalarial medicines4. Historically and as projected,
Asia has the potential to influence the malaria epidemiol-
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ABSTRACT
Asia ranks second to Africa in terms of malaria burden. In 19 countries of Asia, malaria is endemic and 2.31 billion
people or 62% of the total population in these countries are at risk of malaria. In 2010, WHO estimated around 34.8
million cases and 45,600 deaths due to malaria in Asia. In 2011, 2.7 million cases and > 2000 deaths were reported. India,
Indonesia, Myanmar and Pakistan are responsible for >85% of the reported cases (confirmed) and deaths in Asia.
In last 10 yr, due to availability of donor’s fund specially from Global fund, significant progress has been made by
the countries in Asia in scaling-up malaria control interventions which were instrumental in reducing malaria
morbidity and mortality significantly. There is a large heterogeneity in malaria epidemiology in Asia.  As a result,
the success in malaria control/elimination is also diverse. As compared to the data of the year 2000, out of 19
malaria endemic countries, 12 countries were able to reduce malaria incidence (microscopically confirmed cases
only) by 75%. Two countries, namely Bangladesh and Malaysia are projected to reach 75% reduction by 2015
while India is projected to reach 50–75% only by 2015.  The trend could not be assessed in four countries, namely
Indonesia, Myanmar, Pakistan and Timor-Leste due to insufficient consistent data.
Numerous key challenges need to be addressed to sustain the gains and eliminate malaria in most parts of Asia.
Some of these are to control the spread of resistance in Plasmodium falciparum to artemisinin,  control of outdoor
transmission, control of vivax malaria and ensuring universal coverage of key interventions.
Asia has the potential to influence the malaria epidemiology all over the world as well as to support the global
efforts in controlling and eliminating malaria through production of quality-assured ACTs, RDTs and long-lasting
insecticidal nets.
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In this paper Asia is referred as an epidemiological block con-
sisting of 19 countries, namely Afghanistan, Bangladesh, Bhutan, DPR
Korea, India, Indonesia, Myanmar, Nepal, Sri Lanka, Thailand, Timor-
Leste, Cambodia, China, Lao PDR, Malaysia, Pakistan, Philippines,
Republic of Korea and Vietnam from  three Regions of WHO, namely
South East Asia  Region (SEAR), Western Pacific Region (WPR) and
Eastern Mediterranean Region (EMR) where malaria is endemic. J Vector Borne Dis 50, December 2013 240
ogy all over the world as well as support the global ef-
forts to control malaria.
The main objective of this paper is to present
comprehensive overview of the malaria situation in the
malaria endemic countries of Asia, highlight the progress
made by the National Malaria Control Programmes in
controlling/eliminating malaria during 2000–11 and to
identify the key challenges that need to be addressed to
sustain the gains and contribute to the long-term goal of
malaria elimination.
Population at risk
In Asia, out of the total population of 3.6 billion, as
much as 62% people are at risk of contracting malaria, out
of which 11% people are at high risk and 50% are at low
risk2 (Fig. 1). Among the population living in malaria en-
demic areas, infants, young children and pregnant women
have been identified as high risk groups. Other groups of
people who are at high malaria risk are mobile population
particularly those engaged in forest-related economy, gem-
mining, fishing, industrial activities and engaged in road
construction work.  In some countries, ethnic minorities,
refugees, displaced persons, tourists and pilgrims also con-
stitute high risk group. Also, most of the people living in
border areas are at high risk of malaria2. Many of these bor-
der areas are characterized by forest and forest fringe areas
with high malaria transmission, poor geographical acces-
sibility, high population mobility, and low population
density. Large-scale population movement from highly en-
demic areas to low endemic zones has contributed substan-
tially to the maintenance and spread of the disease5–6.
The malaria epidemiology is closely linked with the
physical environment. The most prevalent malaria vec-
tors are Anopheles culicifacies (Diptera: Culicidae), found
in abundance in the plains; An. dirus, that breeds pre-
dominantly in forested areas and An. minimus, that is wide-
spread in the forest-fringe areas. Most of the population
in Asia lives in rice-growing areas and the plains, which
are generally free of malaria transmission. The at-risk
population are those who live in remote villages in or
close to the forested and border areas where malaria vec-
tors thrive and also accessibility to health services is very
poor in these areas.
Disease burden
The burden of malaria in Asia is high and vary from
country to country (Table 1). In 2011, four million malaria
cases (presumed + confirmed) were reported, out of which
2.7 million cases could be confirmed by either microscopy
or by RDT. Out of confirmed cases, >50% cases were due
to P. falciparum (for calculation of Pf% only microscopi-
cally confirmed cases were considered because almost all
the countries were using monovalent RDTs which can dis-
tort the P. falciparum proportion in the region) and 2030
malaria deaths were reported2 (Table 1). It is important to
notice that India, Indonesia, Myanmar and Pakistan are
major contributors and account for >  85% of the total con-
firmed cases and reported deaths in Asia during 2011 (Table
1). In the above mentioned countries, malaria burden within
the country is not uniform and much higher mortality has
been observed in certain geographical areas. In many coun-
tries, it has been observed from the national data that the
high malaria incidence rates were mostly reported along
the border areas with high population mobility, and low
population density9–10.
It should be noted that the country level data provide
trends only and do not reflect the real malaria burden as the
national data mainly cover the passive case detection from
the public health facilities only. Further, the differences in
diagnosis and reporting of malaria cases, and different treat-
ment seeking behaviours by population, etc. make this is-
sue more complicated. In most of the countries in Asia, there
is no systematic inclusion of data from private practitioners,
traditional healers, faith base organizations, self-medica-
tion, treatment by pharmacists and in some cases even data
from community health workers is missing from the na-
tional data. All the above problems made it difficult to
quantify the malaria burden accurately. Despite of the
known limitations, the routine health information system
should be recognized as useful, if not perfect, as the same
is providing country information on major disease trends
and mostly the sole source for detecting epidemics11–13. Fig. 1: Population at risk of malaria in Asia 2011. 241 Bhatia et al: Malaria successes and challenges in Asia
In view of the above mentioned shortcomings and to
have a comprehensive picture of malaria disease burden
among the countries, WHO came forward with a method
to estimate the said burden in any country in 2008 which
can be updated using routine data every year14. Using that
methodology, in 2010, WHO estimated around 34.8 mil-
lion cases of malaria, and 45,600 deaths annually2 in Asia
(Fig. 2). The estimated cases and deaths vary from 757 cases
and no deaths to 24 million cases and 29,400 deaths in the
WHO member countries2. This implies that the malaria sta-
tus among the countries of Asia as well as their contribu-
tions to global burden are, however, not uniform.
Huge diversity in malaria situation
As mentioned in the previous section, there is a huge
diversity in malaria epidemiology which include diver-
sity and heterogeneity of vector species15–17, duration of
transmission, various malaria paradigms, and population
groups affected by malaria18. This diversity is also ex-
tended to prevailing malaria parasites formula also. In
some countries, only P. vivax exists, viz. DPRK and Re-
public of Korea whereas there are some countries with
predominance of P. falciparum with >65% of the micro-
scopically confirmed cases, viz. Bangladesh, Cambodia,
Myanmar, Timor-Leste, Laos and Philippines (Table 1).
Also, there are four countries that are vivax dominated,
namely Afghanistan, Malaysia, Nepal and Sri Lanka
where from >80% of the microscopically confirmed cases
of P. vivax are reported and three countries, namely
Bhutan, India and Thailand where P. falciparum cases
remain between 40 and 60%. Malaria situation vary sub-
stantially between countries and within a country, al-
though common agendas exist, few countries and regions/
areas need  some unique solutions depending upon the
local epidemiology and appropriateness to the place us-
ing local resources and communities. Success of village
malaria workers/volunteers in Bangladesh, Cambodia, se-
lected areas of India, Myanmar, Sri Lanka and Vietnam13
are the few examples that can be replicated.
Table 1. Malaria profile of Asia 2011
Country Presumed Confirmed Micro- Percent Micro- P. vivax Pf% Malaria
and confirmed cases (Micro- scopically suspected scopically attributed
malaria cases scopically + RDTs) confirmed malaria confirmed deaths
cases cases tested P. falciparum
Afghanistan 482,748 77,549 77,549 56.7 5,581 71,968 7.2 40
Bangladesh 51,773 51,773 20,232 100 17,543 2,579 86.7 36
Bhutan 207 194 194 100 87 92 44.8 1
Cambodia 57,423 57,423 13,792 100 7,054 5,155 51.1 94
China 4,498 3,367 3,367 100 1,370 1,907 40.7 33
DPRK 16,760 16,760 16,760 100 0 16,760 0 0
India 1,310,367 1,310,367 1,310,367 100 665,068 645,299 50.8 753
Indonesia 1,322,451 256,592 256,592 53.2 125,412 113,664 48.9 388
Lao PDR 17,904 17,835 6,226 100 5,770 442 92.7 17
Malaysia 5,306 5,306 5,306 100 973 2,422 18.3 –
Myanmar 567,452 465,294 91,752 91.6 59,604 28,966 65 581
Nepal 71,752 3,414 1,910 63.8 219 1,631 11.5 2
Pakistan 334,589 334,589  50 – –   NA –
Philippines 9,552 9,552 9,552 100 6,877 2,380 72 12
Republic of Korea 838 838   56 782 0
Sri Lanka 175 175 175 100 12 158 6.9 –
Thailand 24,897 24,897 14,478 100 5,710 8,608 39.4 43
Timor-Leste 36,064 19,739 19,739 92.8 14,261 3,758 72.2 16
Vietnam 45,588 16,612 16,612 99.1 10,101 5,602 60.8 14
Asia 4,360,344 2,672,276 1,864,603 95.8 925,698 912,173 49.6 2,030
NA—Not available. Note: Pf percentages are calculated based on microscopically confirmed Pf cases only. Source: World Malaria Report 2012.
Fig. 2: Estimated cases and deaths in Asia 2010. Source: World
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Depending upon malaria epidemiology, malaria sta-
tus and local conditions as mentioned above, there is huge
diversity between countries regarding control and elimi-
nation phases of malaria in Asia. Of the above mentioned
19 malaria endemic countries, two countries, namely Sri
Lanka and Korea are in elimination phase, three coun-
tries, namely Bhutan, DPR Korea and Malaysia are in
pre-elimination phase, two countries, namely Philippines
and China are progressing towards sub-national level
elimination where as India, Nepal and Thailand could po-
tentially move towards the pre-elimination phase by con-
tinuing their progress, assuring that all malaria cases are
laboratory confirmed and inclusion the private sector in
the health reporting2 (Fig. 3).
The above mentioned diversity is also visible in de-
mographic, economic and health characteristics of the
countries which are engaged in malaria elimination (in-
cluding pre-elimination and sub-national level elimina-
tion). There are seven countries of the region which fall
under this category and out of these, one country belongs
to lower income economy, four under lower middle in-
come group while one each in higher-middle and higher
income economy categories. There is huge diversity in
population which vary from 0.7 million in Bhutan to >1.3
billion in China. Similarly, life expectancy vary between
66 and 79 yr at birth, gross national income per head,
health expenditure per head and private health expendi-
ture (percent of total health expenditure) vary from US $
1890–21,530, US $ 14–1168 and 14–67% respectively19.
Varying success in malaria control in Asia
Between 2000 and 2011, the countries in Asia have
made good progress in controlling the disease.This success
is due to several factors. One of the main reasons for achiev-
ing massive success was that national efforts and substan-
tial investments in malaria control have yielded dividends
in scaling-up evidence-based interventions that were
adopted as part of their Malaria National Strategic Plans
by the countries2, 20–21. Also, the national efforts and com-
mitments have been complemented by several international
development partners and UN agencies. Improved surveil-
lance, monitoring and evaluation, active involvement of
Fig. 3: Huge diversity in malaria endemic countries of Asia (Philippines and Thailand are involved in sub-national level elimination). 243 Bhatia et al: Malaria successes and challenges in Asia
ducting IRS activity (Table 2). As a result of access to
increased interventions, malaria morbidity and mortality
have declined significantly in Asia. As compared to the
data of the year 2000, the malaria incidence (confirmed
by microscopy + RDTs) and mortality reduced by 34 and
79% respectively (Fig. 4).
As there is a huge diversity in malaria situation in
Asia, there has been varying degree of success in con-
taining/eliminating this disease in this region. The selected
countries where confirmed malaria cases declined by
>50% during 2000–11 are shown in Fig. 5.
The success rate among the countries which had al-
ready reduced their burden and among the high endemic
countries was not the same. The impact on countries un-
der varied malaria control/elimination phases were dif-
ferent as shown in Fig. 6.
Fig. 4: Trends of malaria incidence and mortality in Asia 2000–11.
Source: World Malaria Report 2012; Country reports
submitted  for WMR 2012.
non-governmental organizations, the hard work of dedi-
cated staff from general health services and national ma-
laria control programmes and community participation in
improving access to malaria control services played a vital
role and made significant contribution to achieve the ob-
jectives of reducing the malaria burden. All these combined
efforts lead to intensification of the interventions for ma-
laria control in almost every country in Asia.
The availability and access to medicines, diagnostics
and other commodities have improved significantly. How-
ever, the same is not in the case of high burdened coun-
tries, namely India, Indonesia, Myanmar and Pakistan.
Similarly, there has been significant increase in the avail-
ability and use of parasitological testing in the last few
years. Except Pakistan, Indonesia, Nepal and Afghani-
stan, the rate of testing of suspected malaria is over 90%
in rest of the countries of Asia (Table 1).
Most of the increase in case finding is attributable to
an increase in use of RDTs. The coverage under long-
lasting insecticidal nets (LLINs) and indoor residual spray
for vector control has increased tremendously. The high-
est number of LLINs are procured during 2010 in many
countries. However, the same is not uniform in all the
countries. As most of the countries are resource stricken,
therefore, population at high risk is given preference over
population at low risk for distribution of LLINs or con-
Fig. 5: Countries with >50% decrease in confirmed cases (micro-
scopically confirmed + RDTs) of malaria in Asia (2000–11).
Source: World Malaria Report 2012
Table 2. Malaria intervention status in Asia (2011)
Country Percent Percent Percent Percent
Population Population antimalarial  ACT
 at high risk at high risk coverage coverage
potentially potentially
covered covered
under ITNs under IRS
Afghanistan 92.6 0 NA NA
Bangladesh 100 0 100 100
Bhutan 100 100 58 100
Cambodia 67.8 0 100 100
China 100 100 NA NA
DPRK 100 100 12 100
India 8.3 19.5 100 100
Indonesia 31.1 1.3 29 53
Lao PDR 48.2 0 100 100
Malaysia 100 100 100 100
Myanmar 24.1 0 96 100
Nepal 100 22.7 91 6
Pakistan 3 0 NA NA
Philippines 100 15.5 NA NA
Republic of Korea 100 0 72 NA
Sri Lanka 100 100 100 98
Thailand 0 7.6 100 100
Timor-Leste 43 11.6 100 100
Vietnam 16.3 10 100 100
Asia 21.6 14.8 100 100
NA—Data not available. Source: World Malaria Report 2012. J Vector Borne Dis 50, December 2013 244
In Asia region, 12 countries have registered decline in
the incidence of microscopically confirmed malaria inci-
dence rates of 75% or more between 2000 and 2011.
Bangladesh and Malaysia are on track to achieve a 75%
reduction by 2015 (a 75% reduction in malaria case inci-
dence) is equivalent to an 8.83% reduction per year (com-
pounded) between 2000 and 2015. Thus, to be on track to
achieve the targets, countries need to have reduced the in-
cidence of malaria by at least 64% between 2000 and 2011,
and India is projected to reduce case incidence by 50–75%
by 2015. It was not possible to discern the direction of trends
in Indonesia, Myanmar, Pakistan and Timor-Leste owing
to inconsistency of reporting overtime2.
The biggest challenge is to bring the above mentioned
five high burdened countries, namely India, Indonesia,
Myanmar, Pakistan and Timor-Leste on track with >75%
reduction in malaria incidence category along with the
peers by 2015. In order to reach the desired goal, much
greater scaling-up is mandatory in the direction of access
to quality interventions in diagnostics, treatment and
LLINs. Innovative approaches are needed to protect the
people who are going to forest areas where LLINs are inef-
fective and special efforts need to be placed for reaching out
to the unreached people. Needless to say that there is a need
of strong political commitment as well as huge investment.
Malaria financing
Funding for malaria control has increased dramati-
cally in the last decade globally. In Asia too, funding has
been increased from US $ 66 million in 2000 to over US
$ 84 million in 2011 but the highest amount of US $ 388
million was available in 2010 in Asia. Global fund con-
tinued to remain the major donor globally as well as in
Asia2, 21. Initially, up to 2005, the total donor’s share was
<50% to the total available funds. The government has
the major share as Global fund started providing grants
from 2002 onwards only and grants were limited to few
countries of the Asia only. But situation started changing
thereafter as more and more countries started getting
grants from the global fund in the region (Fig. 7). How-
ever, in 2011, the government funding again exceeded
from donor’s contribution. It is important to notice that
government commitment for malaria is reflected ad-
equately through increased funding every year by almost
Fig. 6: Summary of trends in reported malaria incidence (microscopically confirmed cases only) 2000–11. Source: World Malaria Report 2012.
Fig. 7: Malaria financing status in Asia 2000–11. Source: World
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all countries during the said period.
Although the total funding for malaria has been in-
creased significantly but still the current funding for ma-
laria programmes falls too short of the amount required to
achieve universal access to malaria interventions2, 22 and
most likely it will reduce further due to global recession.
This implies that funding needs to be increased from exist-
ing levels through innovative financing, viz. bond mecha-
nisms, taxes on discretionary items, insurance schemes and
other fee-based initiatives and/or that malaria control
programmes should seek cost savings, viz. more effective
LLINs procurement, integrated approaches to case man-
agement and voluntary pooled procurement across coun-
tries, so that more can be done with existing funds.
In many settings, LLINs and other vector control in-
terventions account for the majority of malaria programme
expenditure2, 20–21. LLINs have a limited lifespan and need
to be replaced every 2 to 3 yr. In 2010, when the procure-
ment of LLINs peaked in most of the Asian countries,
funding is urgently needed to replace LLINs in 2013. Also,
the overall levels of funding and the timing of funding is
also critical. Experience has repeatedly shown that weak-
ening of malaria control efforts leads to resurgences in
malaria, with reductions in funding being the most im-
portant contributing factor. It is, therefore, essential that
levels of funding for malaria control are at least main-
tained at previous levels if outbreaks are to be avoided,
and increased if further reductions in malaria cases and
deaths are to be attained.
Challenges
There are innumerable challenges that are obstructing
the way of the Malaria Control Programmes of the mem-
ber countries to reach the desired goal of malaria elimina-
tion in Asia. Some of them are summarised as under:
Plasmodium falciparum resistance to artemisinin
The emergence of P. falciparum resistance to artemis-
inin23–27 in Asia is the biggest threat to the entire world
(Fig. 8). The Greater Mekong sub-region has been the
epicenter for emergence of resistance in malaria parasites
to several antimalarials in the past. These resistant para-
sites have moved from Mekong to other countries and
even Africa.
So far, artemisinin resistance is restricted to Greater
Mekong sub-region and the same will not be allowed to
fulminate and spread22. Initial reports from Myanmar
showed that resistance has not spread from earlier foci
which is a good news. ACT resistance is the single
factor that can neutralize the gains made in malaria
control in the past decade. In the words of Dr Margaret
Chan, “it is no exaggeration for me to say that the conse-
quence of widespread resistance to artemisinins would be
catastrophe”28.
Resistance in micro-organisms is a complex prob-
lem which has behavioural, educational, biological,
technical, economic and regulatory aspects. All these need
to be addressed comprehensively and vigorously to pre-
serve the efficacy of ACT, which is currently our best bet
against malaria. The world can not afford to lose this tool.
WHO has a global strategy for the prevention and con-
trol of artemisinin resistance which needs to be imple-
mented in right earnest.
Control of outdoor transmission
It is linked to occupations, viz. agro-forestry, rubber
plantation, mining, road and dam construction, etc. It is
not amenable for current tools such as indoor residual
spraying and long-lasting insecticidal nets to deal with it.
Control of vivax malaria
It is also one of the major technical challenges for
malaria control in Asia. The problem of vivax malaria is
often unnoticed. Factors influencing the dynamics of P.
vivax transmission are similar to that of P. falciparum,
but due to its biological characteristics, vivax malaria is
more difficult to control than falciparum malaria. It is
stronger to survive in natural conditions as compared to
Fig. 8: Sites where suspected or confirmed artemisinin resistance has
been detected as of 2012. Source: Emergency response to
artemisinin resistance in the Greater Mekong sub-region:
Regional framework for action 2013–15; WHO 2013. J Vector Borne Dis 50, December 2013 246
P. falciparum. It is now increasingly realized that mor-
bidity load due to vivax malaria is quite high and is likely
to continue for longer period affecting the economic gains.
The problem has been compounded by the emergence of
chloroquine resistance in P. vivax in Indonesia, Papua
New Guinea, Myanmar 29–30, etc. It is therefore, increas-
ingly realized that problems related to vivax malaria
should be addressed and rational control measures need
to be intensified31. New drugs are needed to replace the
14-day treatment with primaquine to circumvent liver
stages and prevent relapse. A diagnostic test for glucose-
6-phosphate dehydrogenase deficiency is also needed for
easy use at point-of-care.
Besides the technical challenges, there are some
programmic challenges also that are listed below:
Counterfeit/substandard drugs and irrational use of drugs
This is a growing problem throughout the Asia but
specially has been the proliferation of counterfeit anti-
malarial drugs on the market. The inadvertent use of fake
drugs has caused deaths from malaria that would other-
wise have been avoidable. The counterfeit and substan-
dard medicines are sold primarily in the informal sector,
along international border areas. The parts of the region
with long borders and many unofficial ports of entry are
most difficult to control and are therefore vulnerable to
the trafficking of fake drugs. Cross-country collaboration,
though essential to halting the counterfeit drug trade, is a
sensitive issue because many sources of counterfeit
antimalarials are from neighbouring countries. In
terms of multicountry studies, a survey conducted in
sites in Cambodia, Lao PDR, Myanmar, Thailand and
Vietnam in 1999/2000 (using convenience sampling)
found that 38% of 104 samples marked as oral artesunate
were fake, containing no active ingredient32–33. A
similar survey conducted in 2002–03 found that 53% of
the 188 artesunate blister packs collected were counter-
feits34.
The misuse of drugs is also an impediment to ma-
laria control in the region. Over- or under-medication can
lead to treatment failure and can allow the parasite to de-
velop resistance. Drug-use surveys have reported a high
degree of self-medication in parts of the Greater Mekong
(for instance, results from a Lao PDR survey showed that
about 53% of respondents self-medicated for malaria35,
which imposes difficulties in ensuring proper drug use).
The problem of irrational drug use has increased with the
expanding role of the private sector in malaria diagnosis
and treatment. In Cambodia, it is estimated that the pri-
vate sector has been the first point of contact for over
70% of people seeking malaria treatment33.
Universal coverage of intervention
Although lot of progress has been made in this direc-
tion still more needs to be done to achieve universal cov-
erage so that all people, and particularly high-risk groups,
have access to key interventions. This requires, among
other things, strengthening the health system, sustainable
financing and innovative delivery mechanism.
CONCLUSION
The success of controlling any communicable dis-
ease lies in accessing the difficult to reach populations.
The epidemiology of malaria is influenced by people liv-
ing in forests, migrant, mobile and ethnic populations.
Strong health systems can bring them into the gambit of
efficient services and evidence based interventions can
reduce disease burden through effective programme and
community participation.
In short, a multitude of challenges need to be faced
to combat malaria. These include productive collabora-
tion, strong political commitment leading to substantial
scaling-up and reaching out to unreached populations,
building strong health systems, addressing resistance in
parasites and mosquitoes which warrant effective regula-
tory machinery, and giving respect to contribution of vivax
malaria which is being neglected but is insidiously be-
coming menacing. But the silver lining along with these
challenges is that there is adequate capacity within Asia
to grow raw material for artemisinin as 80% of the global
production of the plant Artemesia annua is in China and
Vietnam, 6 of the 9 WHO pre-qualified manufacturers of
ACT are in Asia, 3 of the 6 manufacturers of RDT are in
Asia and 4 of 10 WHO approved manufacturers of insec-
ticide treated nets operate from Asia. This vibrant pharma
industry is a great boon for Asian countries.
Malaria is a health problem but not a problem of health
sector alone. A multi-sectoral response with development
and implementation of Healthy Public Policies that pro-
vide a conducive environment and assured community
participation are essential. Asia may have only small por-
tion of the global burden of malaria but it has the poten-
tial threat to global health security. Containing malaria in
Asia is critical to global public health. The industry in
Asia can provide support to entire world in meeting re-
quirements of medicines and commodities, given the right
encouragement. Now with the availability of knowledge,
lessons learnt from the past and availability of efficient
tools which can be further improved and distributed
through innovative delivery mechanisms, malaria could
certainly be contained/eliminated in Asia. Just it needs to
work in planned and comprehensive manner to achieve
the objective of this article. 247 Bhatia et al: Malaria successes and challenges in Asia
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